Drug-Induced Seizure Risk During Acute Emergencies: Clinical Insights and Evidence-Based Management

Abstract

Drug-induced seizures represent a considerable clinical challenge during acute emergencies, with risks heightened by polypharmacy, underlying comorbidities, and the urgent use of pro-convulsant agents. This review synthesizes current epidemiological data, elucidates the mechanistic pathways implicated in drug-induced seizures, and provides guidance on risk stratification, diagnosis, and management in acute care settings. Emphasis is placed on recent evidence, guideline-based recommendations, and the practical implications for clinicians managing high-risk populations.

Introduction

Acute emergencies often necessitate rapid pharmacologic interventions, but certain medications can precipitate seizures, complicating clinical outcomes. Recognition and management of drug-induced seizures are critical for physicians, particularly in emergency departments, intensive care units, and toxicology settings. This review aims to provide a comprehensive, evidence-based overview of the incidence, mechanisms, clinical features, and management strategies for drug-induced seizures in acute emergencies, integrating recent research and expert recommendations to inform clinical practice.

Epidemiology / Disease Burden

Seizures induced by pharmacologic agents constitute a significant proportion of acute symptomatic seizures encountered in emergency and critical care. Epidemiological studies estimate that drug-induced seizures account for 9–21% of adult status epilepticus cases in emergency departments. Common precipitants include antidepressants (particularly bupropion and tricyclics), antipsychotics, antibiotics (notably beta-lactams and fluoroquinolones), stimulants, and withdrawal from sedative-hypnotics. The risk is amplified in populations with underlying neurological disorders, renal or hepatic dysfunction, and in cases of deliberate or accidental overdose. Reporting biases and under-recognition may obscure the true incidence, emphasizing the need for heightened clinical vigilance.

Pathophysiology

The pathophysiological basis for drug-induced seizures varies with the offending agent but commonly involves disruption of inhibitory neurotransmission, heightened excitatory activity, or metabolic derangements. Agents such as beta-lactam antibiotics and fluoroquinolones lower the seizure threshold by antagonizing GABAA receptors, whereas antidepressants may enhance noradrenergic and serotonergic transmission, precipitating cortical hyperexcitability. Tramadol and meperidine are notable for their dual mechanisms, affecting both GABA and opioid receptors. In acute overdose, neurotoxicity may also result from direct cellular injury, ion channel dysfunction, or mitochondrial impairment. These mechanistic insights are crucial for targeted management and risk mitigation.

Risk Factors

Several risk factors potentiate the likelihood of drug-induced seizures in acute emergencies. Patient-specific variables include age extremes, prior history of epilepsy, concurrent CNS pathology, renal or hepatic impairment, and electrolyte imbalances (notably hyponatremia and hypocalcemia). Polypharmacy and co-ingestion of other pro-convulsant substances further increase risk. Drug-specific factors encompass high dosage, rapid escalation, intravenous administration, and the inherent epileptogenic potential of certain agents. Recognizing these risk profiles facilitates early identification and tailored intervention.

Clinical Features

Drug-induced seizures most frequently present as generalized tonic-clonic events, though focal seizures, myoclonus, or non-convulsive status epilepticus may also occur. Clinical onset is typically within hours of drug exposure or overdose, but delayed presentations are possible, especially with agents possessing long half-lives or active metabolites. In severe cases, seizures may be recurrent or progress to status epilepticus, with attendant risks of hypoxia, metabolic acidosis, rhabdomyolysis, and secondary brain injury. Associated symptoms confusion, agitation, autonomic instability may complicate diagnosis, particularly in the context of polyintoxication or altered mental status.

Diagnosis

Diagnosis of drug-induced seizures relies on a high index of suspicion, thorough medication history, and exclusion of alternative etiologies such as metabolic disturbances, infection, or structural brain lesions. Laboratory evaluation should include serum drug levels (where available), toxicology screening, metabolic panel, and assessment of renal and hepatic function. Electroencephalography (EEG) is valuable in identifying non-convulsive seizures and subclinical status epilepticus, particularly in critically ill or sedated patients. Neuroimaging may be warranted to exclude acute structural abnormalities, especially in first-time seizure presentations.

Treatment & Management

Initial management prioritizes airway protection, cardiorespiratory stabilization, and rapid seizure termination. Benzodiazepines (e.g., lorazepam, diazepam, midazolam) are first-line agents for acute seizure control. In refractory cases, second-line antiepileptics such as levetiracetam, valproate, or phenytoin may be employed. Identification and discontinuation of the offending drug are critical. Supportive measures include correction of metabolic derangements and monitoring for complications such as hyperthermia or rhabdomyolysis. In cases of known or suspected overdose, specific antidotes (e.g., flumazenil for benzodiazepine toxicity, naloxone for opioid-induced seizures) may be indicated, although caution is warranted due to the risk of precipitating withdrawal or recurrent seizures.

Recent Advances / Emerging Therapies

Recent advances in the management of drug-induced seizures focus on rapid diagnostics, risk stratification tools, and novel antiepileptic agents. Point-of-care EEG and advanced neuroimaging have facilitated earlier detection of subclinical seizures. Pharmacogenomic profiling may, in the future, enable personalized risk assessment for seizure susceptibility associated with specific drugs. New-generation antiepileptics with favorable side effect profiles, such as brivaracetam and lacosamide, are being investigated for efficacy in toxicological seizures. Additionally, multidisciplinary toxicology teams and clinical decision support systems are improving real-time management and outcomes in acute care settings.

Guideline Recommendations

Current guidelines from the American Epilepsy Society, Neurocritical Care Society, and toxicology organizations emphasize prompt recognition, immediate seizure termination, and identification of the causative agent. Guidelines advocate for benzodiazepines as first-line therapy, followed by additional antiepileptics if seizures persist. Continuous EEG monitoring is recommended for patients with persistent altered mental status. In cases of status epilepticus, escalation to anesthetic agents may be necessary. Prophylactic antiepileptic therapy is generally not indicated unless ongoing risk factors exist. Clinicians are urged to individualize management based on the specific drug, patient comorbidities, and clinical context.

Conclusion

Drug-induced seizures in acute emergencies pose significant diagnostic and therapeutic challenges, demanding a systematic, evidence-based approach for optimal patient outcomes. Early recognition, identification of risk factors, and adherence to established management protocols are essential. Ongoing research and technological innovations hold promise for improved detection, risk prediction, and individualized therapy. Continued education and awareness among healthcare providers remain pivotal in reducing morbidity and mortality associated with drug-induced seizures in emergency settings.